Tom John

Biography

I recently published a study demonstrating that Cancer Testis (CT) antigens are not only poor prognostic markers, but also predict tumors likely to respond to chemotherapy. What is unclear is whether inducing these antigens to be expressed using demethylating agents also increases the likelihood of response to chemotherapy. I am using cell lines and xenografts to establish whether this observation can be used to clinically improve treatments for patients with lung cancer. I am also involved mesothelioma sequencing studies and the investigation of novel biomarkers that correlate with clinical endpoints.

Research Interest

Cancer diagnostics, chemotherapy, lung cancer, tumor biology